State of Parkinson's Research, July 2026

A dated, reproducible monthly snapshot of the Parkinson's clinical trial landscape, archived 2026-07-01 so the figures stay citable over time.

Headline Figures

• Recruiting trials tracked: 502
• New this month: 0
• Phase 3 trials: 11
• Countries with trial sites: 43
• Interventional: 354
• Observational: 148
• Average minimum age: 31 years
• Total ever opened (lifetime, survivorship-immune): 0

Month-over-Month Movement vs June 2026

• Recruiting trials: 502 vs 506 last month, down 4 (-1%)
• Phase 3 trials: 11 vs 11 last month, unchanged 0 (+0%)
• Countries with trials: 43 vs 44 last month, down 1 (-2%)
• Interventional trials: 354 vs 355 last month, down 1 (+0%)

Takeaways

• As of July 2026, 502 Parkinson's trials are recruiting across 43 countries.
• That's down 4 from June 2026 (-1%).
• The most common research focus among recruiting trials is Alpha-synuclein (3 trials).

Top Countries

• United States: 169 recruiting trials
• China: 60 recruiting trials
• Italy: 41 recruiting trials
• Turkey: 29 recruiting trials
• United Kingdom: 29 recruiting trials
• France: 28 recruiting trials
• Canada: 25 recruiting trials
• Germany: 24 recruiting trials
• Netherlands: 18 recruiting trials
• Spain: 18 recruiting trials

Top Drug Classes

• alpha-syn: 3 trials
• DBS: 2 trials
• monoclonal-antibody: 2 trials
• GBA: 1 trials
• focused-ultrasound: 1 trials
• gene-therapy: 1 trials

Top Sponsors

• University of Minnesota: 11 trials
• VA Office of Research and Development: 9 trials
• Xiangya Hospital of Central South University: 7 trials
• University of Alabama at Birmingham: 6 trials
• Beijing Tiantan Hospital: 6 trials
• University of Exeter: 5 trials
• Medical University of South Carolina: 5 trials
• Michael J. Fox Foundation for Parkinson's Research: 5 trials
• Radboud University Medical Center: 5 trials
• AbbVie: 5 trials

See the live State of Parkinson's Research dashboard for the current interactive picture.